This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content

(Circulation. 2006;114:1.)
© 2006 American Heart Association, Inc.

Issue Highlights

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	CARDIOVASCULAR OUTCOMES WITH ATRIAL-BASED PACING COMPARED WITH VENTRICULAR PACING: META-ANALYSIS OF RANDOMIZED TRIALS, USING INDIVIDUAL PATIENT DATA, by Healey et al.

 
Dual-chamber atrioventricular (AV) pacing has long been viewed as more closely approximating normal physiology than single-chamber ventricular pacing and is favored by many cardiologists. The superiority of AV pacing has not, however, been consistently demonstrable in randomized trials. Healey and colleagues conducted a detailed meta-analysis comparing these 2 pacing modes in patients with bradycardia. In over 35 000 years of patient follow-up, AV pacing reduced atrial fibrillation. There was a favorable trend toward reduction in stroke. The magnitude of these benefits is not sufficient, however, to translate to a reduction in mortality. These results should help inform decisions for selection of chronic pacing therapy in patients with sinus rhythm and bradycardia. See p 11.

	RENAL FUNCTION AND EFFECTIVENESS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR THERAPY IN PATIENTS WITH CHRONIC STABLE CORONARY DISEASE IN THE PREVENTION OF EVENTS WITH ACE INHIBITION (PEACE) TRIAL, by Solomon et al.

 
Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce morbidity and mortality in patients with left ventricular dysfunction or heart failure and after an acute myocardial infarction. In patients at high risk for cardiovascular disease, the results have been mixed, with positive results seen in the Heart Outcome Prevention Evaluation (HOPE) trial and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and negative results in the Prevention of Events with an ACE inhibitor (PEACE) trial. In this issue of Circulation, the PEACE investigators evaluated the importance of renal function on the effectiveness of the ACE inhibitor trandolapril. They demonstrated that in patients with reduced estimated glomerular filtration rate that trandolapril improved mortality while in those with normal renal function, no mortality benefit was seen. These findings have . . . [Full Text of this Article]

This article has been cited by other articles:

				B. J. Leavitt, C. S. Ross, B. Spence, S. D. Surgenor, E. M. Olmstead, R. A. Clough, D. C. Charlesworth, R. S. Kramer, G. T. O'Connor, and for the Northern New England Cardiovascular Diseas Long-Term Survival of Patients With Chronic Obstructive Pulmonary Disease Undergoing Coronary Artery Bypass Surgery Circulation, July 4, 2006; 114(1_suppl): I-430 - I-434. [Abstract] [Full Text] [PDF]